Is the price fair?
What ENOV's price assumes
Enovis Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 0.57× revenue.
0.57
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.8%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; revenue has grown +13% a year over the last three.
- Price / book
- 0.88
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.88
- EV / EBIToperating margin −47%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.14
- Free cash flow, trailing twelve months
- $36M
- Market capitalisation
- $1.26B
- 3-year revenue growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.